### Consequences of EU REACH Authorisation of Lead

Lisa ALLEN, Senior Regulatory Affairs Manager, ILA 22 June 2023







#### WHAT IS REACH AUTHORISATION?

EU regulatory process designed to "progressively replace Substances of Very High Concern" (SVHCs) by suitable alternative substances or technologies where economically and technically viable"

#### Inclusion of a substance in **REACH Annex XIV** means that:

- A transition period will apply
- Companies need to apply to the European Commission and be granted permission to continue use
  - No suitable alternative substance or technology available, and
  - Research and development plan in place to identify suitable alternative, and
  - Positive socio-economic cost-benefit
- Authorisation is time-limited: companies need to reapply
- Articles made outside the EU can still be imported, unless restricted



Authorisation listing applies regulatory pressure on continued use of a substance. It increases uncertainty and risk for downstream users

Designed to stimulate substitution and innovation: identify alternative substances in processes or use an alternative technology that
does not contain the SVHC



#### REGULATORY PROCESS – AND STATUS OF LEAD



# Step 1 Substances of very high concern (SVHC)

- Registry of SVHC intentions until outcome
- Preparing the SVHC dossier
- Public consultation
- Adding substances to the Candidate List



# Step 2 Recommendation for inclusion in the Authorisation List

- Prioritisation
- Draft recommendation
- Consultation
- ECHA MSC opinion
- ECHA Recommendation for inclusion in the Authorisation List

Pb metal & 11 Pb compounds now at same point in REACH Authorisation process



## Step 3 Inclusion in REACH Annex XIV

Commission draft regulation Interservice consultation REACH Committee vote

- Scrutiny by European Parliament and Council
- Regulation amending Annex XIV published




# Step 4 Application for Authorisation

- Application for Authorisation
- Public consultation
- RAC and SEAC opinions
- Commission decision (REACH Committee vote)
- Implementation
- Review report, if wishing to renew Authorisation



# POTENTIAL TIMELINE FOR LEAD – AND THE BIGGER PICTURE

- ECHA Recommendation issued to European Commission April 2023
- REACH Revision tabled 2H 2023
- European Parliament elections 1H 2024
- Influence of geopolitical events
- Supply chain security
- Raw materials supply and demand






#### INDUSTRY'S RESPONSE TO THE CHALLENGE


#### Aim: Lead metal is not included in REACH Annex XIV

- Adoption of alternative risk management measures that do not negatively impact battery and other critical uses, ensuring policymakers:
  - Recognise the societal and economic benefits of a strategically autonomous, key raw material
  - Work with Industry to identify and use more effective and proportionate measures
  - Appreciate the unprecedented number of Applications for Authorisation that would be submitted





## International Lead Association





# Lead Solution Matters







International Lead Association


2,176 followers





#### **INCREASING THE REACH**








# WHAT'S THE OUTLOOK?



- Reassurance *for now* but no certainty
  - Once recommended, always eligible
- Under constant review
  - Political climate post-election
  - Changes via REACH Revision
  - Member State and Commission activity
- Maintain watching brief
- Continue to educate and inform
- Ready to act further where needed



#### WHY ECHA'S RECOMMENDATION SHOULD BE REJECTED?

We believe the Commission should reject ECHA's recommendation to include lead metal in the REACH Authorisation List because it would:

- 1. Hamper the EU's ability to achieve key policy objectives, including climate change goals as well as supporting strategically autonomous and essential industrial infrastructure
- 2. Reduce Europe's resilience to geopolitical events by increasing its reliance on Third Countries with lower environmental and social standards
- 3. Threaten skilled jobs and future growth opportunities across multiple Member States
- 4. Lack proportionality given the existing framework of legislation and ongoing reviews
- 5. Result in thousands of Applications for Authorisation without benefit to human health
- 6. Stifle innovation and long-term investment in the EU, even in applications with good growth potential



# Thank You!



**International Lead Association:** 

www.ila-lead.org/

Twitter: @ila\_lead

**LinkedIn:** International Lead Association



**Charge the Future:** 

www.chargethefuture.org/

Twitter: @ChargeTheFuture LinkedIn: Charge the Future



Lead *Matters*:

www.leadmatters.org/